Showing posts with the label Heparin-Induced ThrombocytopeniaShow all
DOACs are options for treating HIT HIT

DOACs are options for treating HIT

Mahitab Hany, BS Pharm, PGDipClinPharm, PGDipClinNutrition February 18, 2022

As a hospital pharmacist, you will get questions about using direct oral anticoagulants (DOACs) for heparin-induced thrombocytopenia (HIT) . We usually treat HIT with IV argatroban or sometimes IV bivalirudin or subcutaneous fondaparinux ( Arixtra ). Then we transition to warfarin ( Marevan ) once the platelet count recovers, usually 150,000/mm3 or higher. Now there&…

Read more
Weigh venous thromboembolism (VTE) prevention strategies in COVID-19 Thromboembolism

Weigh venous thromboembolism (VTE) prevention strategies in COVID-19

Abdelwahab Ward, BS Pharm, PharmD February 20, 2021

Clinicians are scrambling to optimize venous thromboembolism (VTE) prophylaxis for hospitalized patients with COVID-19. Data suggest these patients have a higher VTE risk than other hospitalized patients. Plus D-dimer and other markers are often elevated in COVID-19 especially in severe cases. But there’s little evidence about optimal VTE prophylaxis in patients wi…

Read more
Heparin-induced thrombocytopenia (HIT) HIT

Heparin-induced thrombocytopenia (HIT)

Abdelwahab Ward, BS Pharm, PharmD September 28, 2020

DESCRIPTION ã…¡ There are two types of heparin-induced thrombocytopenia (HIT)... Type 1: Isolated HIT develops early in heparin therapy and is benign. No resultant bleeding or thrombotic complications. HIT type 1 NOT mediated by the immune system (passive heparin binding to platelets resulting in a modest shortening of the platelet life span). The platelet count rarel…

Read more